These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25083527)

  • 1. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
    Lacquaniti A
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083527
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
    Muto S; Kawano H; Higashihara E; Narita I; Ubara Y; Matsuzaki T; Ouyang J; Torres VE; Horie S
    Clin Exp Nephrol; 2015 Oct; 19(5):867-77. PubMed ID: 25663351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT
    Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
    Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Li X; Li W; Li Y; Dong C; Zhu P
    Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
    N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
    Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
    Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.
    Kawada T
    Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
    Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A
    Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
    Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystic kidneys can now be treated].
    Schumacher B
    MMW Fortschr Med; 2015 Sep; 157(15):26. PubMed ID: 26349712
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Dandurand A; Ouyang J; Czerwiec FS; Blais JD;
    Nephrol Dial Transplant; 2018 Mar; 33(3):477-489. PubMed ID: 28379536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS;
    N Engl J Med; 2012 Dec; 367(25):2407-18. PubMed ID: 23121377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.